All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Clinical Trial Club | Optimal treatment sequencing in anemic MF

Mar 13, 2024

Bookmark this article

On February 26, 2024, Scientific Education Support hosted a Clinical Trial Club entitled “Treatment sequencing for anemic myelofibrosis.” This live webinar was part of the MPN Hub Clinical Trial Club webinar series, “Novel agents for the treatment of anemic myelofibrosis.”  

During the live webinar, myeloproliferative neoplasms expert, Angela Fleischman, discussed optimal treatment sequencing in anemic myelofibrosis. She began by outlining when to initiate therapy and first-line therapy considerations, before discussing treatment options for relapsed/refractory disease. 

Fleischman then reviewed key data from recent and ongoing clinical trials, including a phase II trial investigating luspatercept and studies evaluating pacritinib, ruxolitinib, and momelotinib 


Subscribe to get the best content related to MPN delivered to your inbox